The deal announced Monday is Sanofi's third of the year so far.
BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business Communications Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christy Rossi - Chief Operating Officer Conference Call Participants Marc Frahm - TD Cowen Laura Prendergast - Raymond James Michael Yee - Jefferies Colleen Kusy - Baird Derek Archila - Wells Fargo Brian Cheng - JPMorgan Reni Benjamin - Citizens Ami Fadia - Needham David Dai - UBS Judah Frommer - Morgan Stanley Sudan Loganathan - Stephens Operator Good morning. My name is Angela and I'll be your conference operator today.
23 Oct 2025 (In 3 months) Date | | - Cons. EPS | - EPS |
7 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
30 Jul 2025 (In 5 days) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
13 Feb 2025 Date | | - Cons. EPS | - EPS |
23 Oct 2025 (In 3 months) Date | | - Cons. EPS | - EPS |
7 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
30 Jul 2025 (In 5 days) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
13 Feb 2025 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Kathryn Haviland CEO | NASDAQ (NGS) Exchange | 09627Y109 Cusip |
US Country | 682 Employees | - Last Dividend | - Last Split | 30 Apr 2015 IPO Date |
Blueprint Medicines Corporation is a precision therapy company focused on developing innovative treatments for genomically defined cancers and blood disorders. With operations both in the United States and internationally, the company pioneers in creating targeted therapies aimed at addressing specific genetic markers within cancerous cells and blood disorders. Initially founded as Hoyle Pharmaceuticals, Inc., it underwent a name change to Blueprint Medicines Corporation in June 2011 and has been advancing in the field of precision medicine since its inception in 2008. Headquartered in Cambridge, Massachusetts, Blueprint Medicines is at the forefront of developing a new wave of targeted therapies aimed at improving the lives of patients with serious genetic diseases.
Blueprint Medicines Corporation's pipeline includes several promising investigational drugs in various stages of development, targeting a range of conditions with significant unmet medical needs:
Additionally, Blueprint Medicines Corporation has forged several strategic collaboration and license agreements to enhance its developmental capabilities and reach. Partnerships with entities like Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd., underline the company's commitment to bringing new, groundbreaking therapies to market through cooperative efforts and shared expertise.